Federated Hermes’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Federated Hermes’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-9	Closed	-$8	–	2316
2022 Q4	$8	Buy	9 +4	+80%	+$5	﹤0.01%	2147
2022 Q3	$1K	Buy	5 +3	+150%	+$7	﹤0.01%	2122
2022 Q2	$1K	Hold	2	–	–	﹤0.01%	2118
2022 Q1	$1K	Buy	+2	New	+$6	﹤0.01%	2153
2020 Q4	–	Sell	-620	Closed	-$7K	–	2375
2020 Q3	$7K	Buy	620 +396	+177%	+$3.62K	﹤0.01%	2005
2020 Q2	$1K	Buy	+224	New	+$858	﹤0.01%	2201

Other funds holding SRNE

Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

OFA

Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return

CGA

Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return

LCM

Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return

STB

S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return

GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return

HFRG

Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return

VFA

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return

GBWM

Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

Federated Hermes's SRNE Position: Q1 2023 in Review

Federated Hermes sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 9 shares — an estimated $8 sold.

Federated Hermes first reported a position in SRNE in Q2 2020 and held it in 6 quarters. The position peaked at $7K in Q3 2020. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

Federated Hermes reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
Federated Hermes sold 9 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $8.
Federated Hermes first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and held it in 6 quarters.
Federated Hermes's Sorrento Therapeutics, Inc. position peaked at $7K in Q3 2020.
34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Federated Hermes's 13F filing for Q1 2023, filed 8 May 2023.